(Q37520646)

20 August 2017

1 reference

title

Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent (English)

1 reference

20 August 2017

1 reference

Yaron Ilan

1

1 reference

20 August 2017

Deborah Elstein

series ordinal

2

1 reference

20 August 2017

Ari Zimran

series ordinal

3

1 reference

20 August 2017

language of work or name

1 reference

16 June 2009

1 reference

Immunology & Cell Biology

20 August 2017

published in

1 reference

20 August 2017

volume

87

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

514-524

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

20 August 2017

1 reference

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher disease as a paradigm of current issues regarding single gene mutations of humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Natural history of Ashkenazi intelligence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Lessons learned from the development of enzyme therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement in Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher disease: unmet treatment needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement therapy for Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

New prospects for the treatment of lysosomal storage diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement therapy: conception, chaos and culmination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement for lysosomal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

A less costly regimen of alglucerase to treat Gaucher's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Imiglucerase and its use for the treatment of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Life expectancy in Gaucher disease type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher disease and cancer incidence: a study from the Gaucher Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher disease and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher's disease with Parkinson's disease: clinical and pathological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Parkinsonism among Gaucher disease carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Parkinsonism in type I Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Epidemiology and natural history of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Mouse CD1-specific NK1 T cells: development, specificity, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

21 January 2018

The biology of NKT cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

NKT cells: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Going both ways: immune regulation via CD1d-dependent NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

The immunological function of iGb3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Regulation of immunity and pathogenesis in infectious diseases by CD1d-restricted NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Immunotherapy with ligands of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Regulation of immune responses by CD1d-restricted natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Role of NK1.1+ and AsGm-1+ cells in oral immunoregulation of experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Adoptive transfer of NK 1.1+ lymphocytes in immune-mediated colitis: a pro-inflammatory or a tolerizing subgroup of cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Regulation of type 1 diabetes by NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

All roads lead to Rome: pathways of NKT cells promoting asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Role of alpha-galactosylceramide-activated Valpha14 natural killer T cells in the regulation of allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Immunoregulatory T cells in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glycolipids as immune modulatory tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Gangliosides as components of lipid membrane domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Aggregation of red blood cells in patients with Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Lipid rafts are required for efficient signal transduction by CD1d.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Harnessing invariant NKT cells in vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

beta-Glycosphingolipids as immune modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Understanding the behavior of invariant NKT cells in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Negotiation of the T lineage fate decision by transcription-factor interplay and microenvironmental signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Th17: an effector CD4 T cell lineage with regulatory T cell ties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Dendritic cells, T cell tolerance and therapy of adverse immune reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Lineage plasticity and commitment in T-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Principles of bioactive lipid signalling: lessons from sphingolipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Sphingolipids and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glycolipids as immunostimulating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Nuclear sphingolipids: metabolism and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide kinase and the ceramide-1-phosphate/cPLA2alpha interaction as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Role of neutral sphingomyelinases in aging and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide: a common pathway for atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Multiple roles for sphingolipids in steroid hormone biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide-enriched membrane domains--structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide-enriched membrane domains in infectious biology and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Molecular targeting of acid ceramidase: implications to cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide-induced cell death in malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Ceramide: a contributor to insulin resistance or an innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Hepatic T cells and liver tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Cellular and molecular mechanisms of liver tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Roles of CD1d-restricted NKT cells in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Role of NKT cells in the digestive system. III. Role of NKT cells in intestinal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Survey of hematological aspects of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Plasticity of Ly49g expression is due to epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

Enzyme replacement therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Lung involvement and enzyme replacement therapy in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Home treatment with enzyme replacement therapy in a 5-year-old girl with type 2 Gaucher disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Increased risk of cancer in patients with Gaucher disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Increased incidence of cancer in adult Gaucher disease in Western Europe

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

A 27-year experience with splenectomy for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Gaucher and Parkinson diseases: unexpectedly related.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Natural autoantibodies in sera of patients with Gaucher's disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Distinct Roles of Dendritic Cells and B Cells in Va14Ja18 Natural T Cell Activation In Vivo

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Protective and pathogenic roles of CD8+ T cells during malaria infection.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

NKT cells and autoimmune diseases: unraveling the complexity.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

iNKT cells in allergic disease.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Cell biology: Taxi service for lipids

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Dissecting lipid raft facilitated cell signaling pathways in cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Expression of nonclassical class I molecules by intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.42

7 January 2021

Identifiers

DOI

10.1038/ICB.2009.42

1 reference

20 August 2017

1 reference